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Combining Provocative Agents of Calcitonin to Detect Medullary
Carcinoma of the Thyroidt
J. C. Sisson, MD,* M. D. Gross, MD,* J. E. Frietas, MD,* C. E. Jackson, M D ,

The presence of clinically undetectable medullary thyroid
cancer can be revealed by characterisdc patterns of calcitonin in serum after the injection of a provocative agent,
pentagastrin or calcium ion. However, in some reports,
medullary thyroid cancer was uncovered in a test with
pentagastrin but not in one with calcium ion, and vice
versa. To reduce the number of erroneous responses, each
provocative agent has been employed in separate tests.
Combining pentagastrin and calcium into one stimulus
should give the advantage of each agent while requiring
less time and fewer analyses in a single test.

and B. G. England, PhD*

cinoma, the combined sdmuli usually, but not always,
elicited a greater rise in serum calcitonin
concentradon
than did the more potent of the two agents alone. However, we encountered no false negative results in any ofthe
methods used: pentagastrin alone, calcium ion alone, or
pentagastrin combined with calcium. Still, normal responses to both agents theoredcally give greater assurance
that medullary cancer and hereditary disease are absent.
The symptoms associated with the provocative tests
the same as, or no worse than, those reported for
agent alone. Serum calcium concentrations increased
few minutes after calcium gluconate was administered,
with practice at infusions, maximum concentrations
held below 14.2 mg/dl.

We combined pentagastrin injection and calcium ion infusion into a single stimulus of calcitonin secretion. Normal
responses to each pharmacologic agent and to the combination were established. In patients with medullary car-

In the proper clinical setting, abnormal concentrations of
serum calcitonin (CT) reliably indicate the presence of
medullary carcinoma of the thyroid gland (MCT) or its
precursor, C-cell hyperplasia. These cancers and premalignant cells usually secrete CT at rates greater than normal.
Since abnormal basal CT levels may already be associated
with incurable metastases, provocative stimuli — particularly pentagastrin and calcium ion — have been used to
produce diagnostic secretory patterns of CT when basal
concentrations are normal and the neoplasm is confined to

were
each
for a
but,
were

Such provocative tests are of special value in detecting
affected relatives of patients with multiple endocrine neoplasia type 2a (1-3) and type 2b (7). Screening programs of
this kind have uncovered MCT in about 50% of family
members, a figure predicted by the autosomal dominant
mode of inheritance. Because the diagnoses were established at early stages, complete resection of the cancers has
apparently been possible (1-3, 6). Nevertheless, there are
reports in which a test using pentagastrin revealed the
cancer, but the injection of calcium ion gave a false
negative result, and vice versa (1). To reduce errors of this
type, some physicians employ each pharmacologic agent
in separate rate tests on individuals at risk for MCT.

the gland (1-6).
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To ascertain the effectiveness of a diagnostic-therapeutic
program for hereditary MCT, patients must be retested
periodically. Equally important are reevaluations of family
members who responded normally to the stimuli in the
initial screening procedures. At present, it seems prudent to
reassess people who are still at risk every one to two years.
However, recurrent testing imposes a burden on affected
families, physicians who administer the studies, and laboratories that process the samples. Indeed, one group found
it logistically impossible to employ both calcium and pentagastrin in separate provocative tests and has therefore
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We prepared radio-labeled tracer by labeling syn-hCT
using a modification ofthe chloramine-T method of Hunter
and Greenwood (8), a World Health Organization syn-hCT
standard (70/234), and a double antibody separation using
a 2.5% solution of polyethylene glycol and sheep antirabbit gamma globulin. Unlabeled ligand (standard or subject's sample) and antibody were pre-reacted for 24 hours
before the radio-labeled tracer was added. The reaction,
contained in an incubation volume of 800 p l , was allowed
to proceed at 4°C for 48 hours before the separating
reagent was added. The separation reaction is complete
within 10 minutes, and separation of antibody-bound and
free tracer was accomplished by centrifugation at 800 g for
30 minutes.

chosen to use only the latter agent (1). A single yet reliable
method that effectively exploits the stimulating qualities of
both pentagastrin and calcium would be welcome.
Wells, et al (3) reported that combining the stimuli, pentagastrin and calcium ion, into a single procedure detected
MCT more frequently than when either provocative agent
was employed alone. Here, using a comparable method in
which injected pentagastrin is immediately followed by an
infusion of calcium gluconate over one minute, we report a
similar but not identical experience: 1) generally, but not
invariably, the combined pharmaceuticals provoked responses equal to or greater than those of the more potent
single agent; 2) no false positive patterns; 3) no false
negative patterns when compared to a single stimulus; and
4) patient acceptance.

Assay sensitivity, based upon the variation observed in the
zero standard tubes, was approximately 5 pg/tube with a
lower limit of detection in serum of approximately 50
pg/ml of serum, based upon the use of a serum sample size
of 100 ul. A second estimate of assay sensitivity, the lowest
point on the standard curve, yielded 10 pg/tube, or 100
pg/ml of serum. The standard curve consisted of 10 points
extending from 5 ng/tube to 10 pg/tube with a 50% inhibition point of 142 pg/tube and a slope of -2.2 Results were
calculated from a weighted least square linear regression
analysis of the binding data after a logit-log transformation.
Interassay coefficient of variation for the 50% point on the
inhibition curve for 12 assays was 9.0%. For 3 quality
control sera that bound at 65%, 47%, and 25% on the
standard curve, the coefficient of variations were 7.7%,
18.1%, and 16.6%, respectively.

Materials and Methods
Controls and Patients
Control data were obtained from 38 paid healthy volunteers, aged 19-35 years. Some individuals served as controls in all three test methods, while others were employed
for only one or two.
Patients were from nine families in which MCT had been
found in more than one member, and all were considered
to manifest multiple endocrine neoplasia 2a (1,2). Nine
were evaluated before thyroidectomy. Two other patients
were considered to have sporadic MCT because the tumor
was unilateral and no relatives had developed the disease;
one was tested before operation, after her diagnosis was
established by needle biopsy.

Parallelism checks for one patient (No. 15), shown in Fig. 1,
represent stimulation studies before and after thyroidectomy. The assay results from the samples of these times
appear parallel to the standard curve. We cannot explain
the source of calcitonin detected in the sera of patientswho
have undergone thyroidectomy. In the early phase of the
study we determined parallelism for all samples, but since
parallelism seemed the rule, only duplicate measurements
were made on blood specimens from later subjects.

Methods
Tests were carried out while the patients and controls were
fasting except for some individuals who were given pentagastrin alone several hours after a meal. We used three
methods: 1) pentagastrin (Peptavlon,® Ayerst Laboratories)
0.5 Mg/kg was injected intravenously over five seconds;
2) caldum, 2 mg/kg, as calcium gluconate, was infused
over one minute at as constant a rate as possible; 3)
pentagastrin given over five seconds was immediately followed by the infusion of calcium over one minute. Blood
specimens were obtained before and at 2, 5, and 15
minutes after the injections were started.

We measured calcium by an automated method using
orthocresolphthalein to develop color (9); the 95% confidence limits of the normal range were 8.8-10.9 mg/dl.

Results

The three methods were carried out in all patients and
controls within a six-week period except for three patients
who required a few months (up to ten) before all tests could
be completed.

Calcitonin values acquired from control subjects in the
three methods are summarized in Table I. Increments of CT
above baseline concentrations conveniently depict responses at two and five minutes after injections, times
when maximal changes have been observed. The basal
concentration of CT in normal men was slightly higher than
that of women, but the difference was not statistically
significant. In the two methods with pentagastrin as a

We measured calcitonin in sera using a radioimmunoassay
developed by one of us (BGE). The method is a nonequilibrium assay that uses antibody developed in a rabbit
immunized against synthetic human calcitonin (syn-hCT).
-6

Calcitonin Detection of Thyroid Medullary Carcinoma

in pg/ml, for pentagastrin -6110, for calcium -1-130, and for
pentagastrin/calcium -6220.

RADIOIMMUNOASSAY FOR CALCITONIN
MICROLITERS OF SERA FROM
PATIENT A S
50

lOu

Three categories of patients are tabulated in Table 11.
Medullary carcinoma was verified histologically, either before or after testing, for patients in the first two categories
(except for patient No. 5, who has not yet undergone
operation but whose test abnormalities were so marked as
to be strong evidence of MCT). Patients with borderline
high or high basal concentrations of CT were allocated to
the first category; normal basal CT values characterized
those in Category 2,

200
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312

CALCITONIN

625

500

In the third group are subjects whose responses were
normal by all methods. They have had MCT completely
removed by operation or are at 50% risk of developing
MCT because of family affiliation.

5Q00

Ipg)

Fig. 1
A standard curve for the radioimmunoassay of CT. Croups of five
samples of sera were obtained from patient No. 15 before and after
thyroidectomy for MCT. Each group constituted a study in which pentagastrin was the provocative stimulus; the time of each sample relative
to the injection of pentagastrin is indicated. When the concentrations of
calcitonin in different volumes of each serum are plotted, parallelism
w i t h the standard curve is inscribed.

The highest increment of CT was seen after the combined
stimuli in six of the 11 patients in Categories 1 and 2. In
several patients the increment of calcitonin concentration
after injection of pentagastrin or calcium alone was less
than 50%' of that obtained with the agents together (e.g.,
patient No. 10). Also, the five individuals (patients No. 1, 3,
6, 7, and 9) whose maximum increment was highest with a
single agent exhibited rises in calcitonin after the combined
stimuli (62-97%) that approached the highest value
achieved by any procedure. Even though the combined
stimuli did not always provoke the largest increments of CT,
this method never gave normal (false negative) responses
when either of the other methods elicited abnormality.
Indeed, no method gave a false negative result.

Stimulus, the increments of CT in men exceeded those in
women, but this difference too was not significant. No
detectable response was observed in many normal
subjects.
Normal ranges were therefore established to be the same
for both sexes: 97.5% of basal values were below 450
pg/ml; but those above this concentration (550 pg/ml)
were considered abnormal. Although increments in normal
women were slightly less than those in normal men, upper
limits of normal were designated from the studies of men:

Pentagastrin produced the well known symptoms of upper
abdominal and lower chest cramping associated with nausea. Calcium caused sensations of general ized warmth and
occasionally nausea. Both control subjects and patients

TABLE I
Calcitonin R e s p o n s e s to Provocative Stimuli in Control S u b j e c t s
Basal C o n c e n t r a t i o n s of Calcitonin ( p g / m l )
Mean ± SD
Women (16)
248 ± 79

Men (22)
274 ± 135
Provocative Tests: Increments in C a l c i t o n i n (pg/ml)
Mean (Range)

Women

Men
Test
Pentagastrin

Calcium

Pentagastrin
plus c a l c i u m

No,
(11)

(11)

(10)

2 min
-1-35
( - 7 0 to +110)

5 min
+ 14
( - 9 0 to +80)

No,

2 min

(8)

+9

+24
( - 9 0 to +130)

+2

(7)

( - 9 0 to +80)

+ 30
( - 9 0 to +180)

+ 50
( - 7 0 to +220)

77

( - 4 0 to +60)

(11)

+4

5 min
+5
( - 3 0 to +60)

( - 5 0 to +70)

+ 26
(0 to +60)

+ 17
( - 5 0 to +150)

+8
( - 5 0 to +100)
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TABLE II
Calcitonin Responses to Provocative Stimuli In Patients
Patient

Age

Calcitonin (pg/ml) as Maximum lncrement*/Basal

Sex

Pentagastrin t

Calciumt

Pentagastrin
plus Calcium

26,500/930
36,400/1,040
86,200/960

24,200/1,180
96,100/950
63,100/680

Category 1: Patients with basal concentrations of >550 pg/ml
l.t
l.t
3.t

30
27
55

12,400/760
64,600/1,020
3,700/580

M
M
F

Category 2: Patients w i t h basal c o n c e n t r a t i o n s of < 5 5 0 p g / m l and a b n o r m a l responses
4.t

22

F

5,11
6,t

15
24
25
34
40
26
50

M
M
F
F
F
F
F

7.x
8,1:
9.t#
lO.T
11,t

(Preop)
(Postop)

11,500/520
1,090/310
400/350
3,700/490"
780/380
310/170
9,500/200
2,400/250**
5,400/430

12,200/370
740/340
650/300
3,000/480
3,300/310
1,040/130
7,100/150
1,900/300
15,300/390

20,600/360
1,610/330
990/350
2,900/300
3,200/270
1,170/110
5,900/200
5,000/160
19,700/270

Category 3: Patients w i t h n o r m a l basal c o n c e n t r a t i o n s and normal responses
12,§
13,§
14,5
15,§
16, II
17, II
18. II
• 19.§#

19
13
12
62
20
23
17
30

F
F
F
M
F
F
M
M

20/290
-10/350
0/400
-10/500
-20/310
-40/500
-90/200
-30/460

10/280
110/390
0/350
-40/450
-10/320
10/430
40/180
-60/510

-10/310
30/360
60/370
-40/490
60/320
40/480
-140/260
-30/440

* Maximum occurred at 2 or 5 r ninutes after injections were started.

t See text for dose schedules,
X MCT confirmed histologically,
8 MCT postoperative state, presumably cured
« At risk (50% risk)
# Apparently sporadic MCT
** Calcium given 3 mg/kg over 10 minutes
ND Not done

the level attained. Values were invariably lower at five
minutes and normal by 15 minutes. The calcium values
after the last 13 infusions did not exceed 14.1 mg/dl. The
infusions were carried out by hand, and with practice they
were administered more smoothly.

reported that the method of combining provocative pharmaceuticals induced no more symptoms than did the more
unpleasant of the single agents. Symptoms were severe in
none and disappeared by four minutes in all.
Serum calcium concentrations were determined in blood
spedmens obtained from all control subjects following the
infusion of calcium gluconate (Table III). These infusions
produced serum calcium concentrations after two minutes
that varied from no change over baseline to a value of 22.5
mg/dl in one woman of the control group. The serum
calcium in this subject fell to 10.4 mg/dl by five minutes,
and it is possible that some of the pharmaceutical was
mixed with the first blood specimen in the catheter. Nevertheless, calcium concentrations reached 15-16 mg/dl in
other indi'^fiduals, and symptoms were generally related to

Basal measurements of caldum were obtained in all patients to exclude the possibility of hypercalcemia. None
had a value greater than 13.1 mg/dl at two minutes afterthe
calcium infusion began.

Discussion
In our studies we did not observe the statistically significant
differences between men and women in the basal concentrations or in stimulated increments of CT that others
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TABLE III
Serum Calcium Concentrations After Calcium Gluconate Infusions*
in Normal Subjects**
Time After Infusion (min)

Serum Calcium (mg/dl)
2

-1

Men
Concentration (Mean ± S,D,)
Increment (Range)

(16) 9,4±0,4

(18) 11,8±1,8
-1,3 to +7,0

(18)10,7±0.7
-0,4 to +2,7

Women
Concentration (Mean ± S,D,)
Increment (Range)

(11) 9,6±0,7

(16)13,8±3,0
0,0 to +12,8

(16) 10,8+0.8
+ 0.5 to +3.6

' 2 mg calcium/kg over 1 minute
' Some subjects served in two methods, calcium alone or pentagastrin plus calcium.
have reported (10-12). Although the sensitivity of our CT
assay may not be as great as that in other laboratories (10,
11), the increments following stimulation readily detect
MCT that is localized and completely resectable. In fact, of
11 individuals who were first identified as abnormal by
provocative testing over three years, two had C-cell hyperplasia, and all but two had localized disease. In follow-up
evaluations subsequent to operation, only the two individuals with regional node involvement have exhibited
abnormalities in annual provocative studies.

Although calcium concentrations greater than 15 mg/dl are
disquieting, these levels lasted only a few minutes and
were well tolerated. Others have reported the increment of
serum calcium concentrations after infusions of 2 mg/kg
over one minute only as a mean value, 2.1 mg/dl (3); the
maximum increments were undoubtedly higher. Nevertheless, if calcium is to be used as a stimulating agent, then, by
whatever technique of administration — including 3 mg/kg
over 10 minutes (4) and 15 mg/kg over 4 hours (13) —
hypercalcemia must be an accepted consequence. With
practice in giving 2 mg/kg over one minute, elevations of
serum calcium above 14 mg/dl can be avoided. Perhaps a
safer alternative to manual administration from a syringe
would be infusing the calcium by a rate-controlling pump.
Precautions should include a preliminary measurement of
calcium concentrations to avoid adding calcium to an
already abnormal level of blood calcium, a state not infrequently found in these patients who are at risk for hyperparathyroidism. In addition, calcium should be avoided in
patients with bradyarrhythmias and in those taking digitalis
preparations.

Combining the provocative agents, pentagastrin and calcium, into a single method usually induced increments in
serum calcitonin as great as, or greater than, either stimulus
used alone. In contrast to the results reported by Wells, et al
(3), this was not an invariable observation. Variability in
responsiveness probably does not relate to progressive
disease over the time of testing (1), which was a few months
in some cases. In fact, MCT generally grows slowly over
years, and ofthe different methods employed in this investigation, the last often did not elicit the greatest response.
This suggests that, in these individuals, we were not observing the changes of progressive disease.

Silva, et al (14) have proposed that a measurement o f t h e
calcitonin/creatinine ratio in a single urine specimen will
serve as the initial evaluation of harboring MCT. While
simplified for the patient, the laboratory technique is complex. If assays on urine are to provide an acceptable rate of
false negative results, many more patients will need to be
studied by this procedure.

When one agent alone appears more potent than the
combination, the resuft very likely relates to random variations in individuals. No evidence exists that either calcium
ion or pentagastrin inhibits the effects of the other.
Experience in many laboratories and clinics over the years
records the significance of CT changes afterthe injection of
pentagastrin or the infusion of caldum. Only one false
positive result has thus far been reported (1). The combination of agents is a potent stimulus of CT secretion and, as
such, could produce more false positive responses than has
been the case when the two pharmaceuticals were employed separately. However, if used primarily as a screening method, subsequent evaluations of suspicious results
with one or both pharmaceuticals alone should provide
additional perspective to the status of an individual.

In this study we encountered no false negative results in
any of the three provocative methods used. Nevertheless,
since pentagastrin and caldum ion have given false negative responses when used alone (1), the use of both agents
together is attractive, especially when the physician wishes
to assure his patient about the absence of cancer and
hereditary disease. Combining the two pharmaceuticals
into a single method minimizes the patient's and physician's time, the amount of blood removed, and the cost of
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calcitonin assays. In view ofthe need for reevaluation over
many years, particularly for members of families who
remain at risk, the method of combined agents has great
appeal.
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